Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2014 Nov 15.
Published in final edited form as: J Immunol. 2013 Nov 15;191(10):10.4049/jimmunol.1302005. doi: 10.4049/jimmunol.1302005

Little peptide, big effects: the role of LL-37 in inflammation and autoimmune disease

J Michelle Kahlenberg *,, Mariana J Kaplan *
PMCID: PMC3836506  NIHMSID: NIHMS528222  PMID: 24185823

Abstract

The innate immune system utilizes many approaches for defense against invading microorganisms, including complement-mediated lysis, engulfment, formation of neutrophil extracellular traps (NETs) and release of antimicrobial peptides (AMPs). While classically thought to be driven by adaptive immunity, the development of autoimmune diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) is increasingly associated with dysregulated innate immune pathways. An emerging theme within this literature is the contribution of AMPs to the development of autoimmune disorders. This is best exemplified in atopic dermatitis and psoriasis where the defensins and the single human cathelicidin, LL-37, may contribute to disease. Further, in the past few years, a role for LL-37 has emerged in the pathogenesis of SLE, RA, atherosclerosis and possibly other diseases. This review discusses the role of LL-37 and its murine ortholog, mCRAMP, in the modulation of immune and inflammatory pathways and their effects on autoimmune and inflammatory diseases.

INTRODUCTION

The innate immune system plays crucial role in defense against microbes as well as in the initiation of inflammatory responses. Antimicrobial peptides (AMP) are an important evolutionarily conserved defense mechanism against bacterial and fungal invasion of eukaryotic organisms. Hundreds of AMPS are synthesized by epithelial cells and lymphocytes(1). While several classes of AMPs exist, LL-37 is the sole member of the human cathelicidin family. This peptide has piqued the interest of the research community because, in addition to its antimicrobial properties, it carries numerous immune system modulating properties which may contribute to autoimmune disease development (Table 1).

Table 1.

Summary of effects of LL-37 on autoimmune and atherosclerosis disease pathogenesis.

Disease Effects of LL-37

Psoriasis
  • -

    ↓ keratinocyte apoptosis(44)

  • -

    ↑ IFNα production through stabilization of extracellular DNA(48)


Systemic Lupus
Erythematosus
(SLE)
  • -

    Stabilizes circulating ICs and allows for IFNα synthesis by PDCs(54)

  • -

    ↑ IL-18 production by macrophages(31)


Rheumatoid
Arthritis (RA)
  • -

    ↑in synovial fluid inflammatory cells(60)

  • -

    ↑ apoptosis of osteoblasts(45)

  • -

    Expression and citrullination of lung LL-37 ↑by cigarette smoking(66, 67)


Atherosclerosis
  • -

    ↑ levels in atherosclerotic plaques may ↑ inflammatory cell recruitment(81)

  • -

    May promote thrombosis by activation of EC(82)

EC=endothelial cell; IC=immune complex; pDC=plasmacytoid dendritic cell;

LL-37

LL-37 is a 37 amino acid cationic peptide generated by extracellular cleavage of the C-terminal end of the 18 kDa hCAP18 protein by serine proteases of the kallikrein family in keratinocytes(2, 3) and proteinase 3 (PR3) in neutrophils(4) (Figure 1). LL-37 is able to form aggregates in solution and lipid bilayers and thus, unlike other antimicrobial peptides, is protected from proteolytic degradation(5). Its positive charge allows it to preferentially associate with negatively charged phospholipid membranes(5). Further, it assumes a primarily α-helical shape during membrane interactions resulting in unilateral segregation of its hydrophobic residues(6). This allows for membrane penetration, formation of transmembrane pores and bacterial lysis (68). Cellular membranes associated with cholesterol, such as those found in mammals, are protected from the pore-forming effects of LL-37; however, this effect can be overcome by higher concentrations of the peptide (9, 10).

Figure 1. L-37 is generated via cleavage of full-length hCAP18 and has numerous immunomodulatory functions depending on environmental and cellular context.

Figure 1

The 18 kDa pro-peptide, hCAP18, is synthesized and stored in granules and lamellar bodies. Following stimulation by pro-inflammatory signals, hCAP18 is released into the extracellular environment and cleaved by proteinase 3 in neutrophils and kallikrein in keratinocytes (green dots) and the N-terminal 37 amino acids form the alpha-helical LL-37 peptide which then dimerizes and trimerizes in solution. Exposure to LL-37 results in recruitment of inflammatory cells, induction of M1 macrophages and stimulation of inflammatory responses such as inflammasome activation and type I IFN production. Type I IFN production is promoted via LL-37 protection of both RNA and DNA, allowing for activation of endosomal TLR7 and TLR9 respectively. LL-37, expressed on the surface of neutrophils is recognized by anti-LL-37 autoantibodies, which promotes NETosis, generating a source of additional LL-37 DNA complexes. However, LL-37 has strong anti-inflammatory effects such as neutralization of TLR4 activation by LPS, downmodulation of inflammatory cytokine responses and preventing invasion and inflammatory responses to pathogenic bacteria.

LL-37 was originally characterized as constitutively expressed in secondary neutrophilic granules(2), However, LL-37 is produced by many cell types including macrophages, natural killer (NK) cells, and epithelial cells of the skin, airways, ocular surface and intestine(10). Regulation of its expression is controlled by inflammatory pathways as well as the vitamin D pathway and endoplasmic reticulum stress(1113). Studies utilizing mice deficient in mCRAMP, the murine orthologue of LL-37, have demonstrated important antimicrobial roles for this peptide. In the skin, LL-37/mCRAMP is required to prevent invasive bacterial infections(14). Similarly, mice deficient in mCRAMP have increased colonization and invasion of pathogenic bacteria in the colon(15) and are more susceptible to urinary tract infections(16). Furthermore, mCRAMP displays protective effects against Clostridium difficile toxin-mediated colonic and ileal damage, while human LL-37 has protective functions on toxin-A mediated inflammatory cytokine production(17). Intriguingly, mCRAMP has also been shown to have protective effects against influenza infection suggesting it also has a role in the anti-viral response(18).

LL-37 influences inflammatory cell recruitment and macrophage phenotype

Besides its antimicrobial functions, LL-37 also has immunomodulatory roles (Figure 1). Indeed, both pro- and anti-inflammatory functions have been assigned to LL-37 and this may be modulated by the microenvironment and disease background. For example, the presence of 10 µg/ml LL-37 during monocyte to macrophage differentiation promotes a pro-inflammatory response, resulting in downregulation of IL-10 and upregulation of IL-12p40. Further, LL-37 directs the plasticity of differentiated macrophages toward an M1 phenotype(19), suggesting the presence of this peptide has a strong influence on macrophage development and cytokine production. Additionally, LL-37 exposure enhances inflammatory cytokine production driven by IL-1β signaling(20). Anti-inflammatory properties of LL-37 are demonstrated by its antagonistic action on IFNγ, TNF-α, IL-4 and IL-12 responses in various cell types(2022). A strong anti-inflammatory response through modulation of TLR signaling is also attributed to LL-37 (see below). Thus, the environmental and cellular context in which exposure to LL-37 occurs is important for determining the direction of the cellular response.

A notable feature of LL-37 is that it also has various chemotactic properties. Acting through the formyl-peptide receptor, FPR2, LL-37 induces migration of neutrophils and eosinophils(23). Other G-protein coupled receptors are similarly activated by LL-37 and may contribute to the chemotactic effects of this peptide(10). Transactivation of the epidermal growth factor receptor by LL-37 induces migration of keratinocytes and thus promotes wound healing(24). LL-37 also modulates the production of chemokines to promote chemotaxis. LL-37 is able to induce transcription of CXCL8 alone and synergizes with TNFα-mediated expression of this chemokine(22). MCP-1/CCL-2, a monocyte recruitment factor is secreted in a dose-dependent fashion following LL-37 stimulation(25). Further, TGF-β released from intestinal epithelial cells following exposure to LL-37 also has important chemotactic effects for epithelial cell migration and the wound healing response(26). Thus, LL-37 released at the site of infection or tissue injury is able to promote the inflammatory response and initiate wound repair.

LL37 and toll-like receptor (TLR) pathways

TLRs are widely-expressed receptors which respond to pathogen-associated molecular patterns (PAMPs). Dysregulation of TLR signaling has been reported to be important for the development of autoimmunity(27). Modulation of TLR function by LL-37 can be considered an anti-inflammatory effect. Indeed, LL-37 downregulates signaling through TLR4 via binding of its ligand, LPS(2, 28), as well as through interruption of TLR4 receptor complex function in dendritic cells and macrophages(29, 30). This results in lower levels of pro-inflammatory cytokine production when LL-37 and LPS are present simultaneously. Similar repression of chemokine release has been noted in epithelial cell lines(25). In vivo, mCRAMP represses the response to 2,4-dinitrofluronbenzene-mediated contact hypersensitivity through pathways which require the TLR4 receptor(29).

Alternatively, depending on the sequence of LL-37 and LPS exposure, the effects of LL-37 on TLR4 responses can be pro-inflammatory. When macrophages are primed with LPS prior to LL-37 exposure, there is enhanced release of TNF-α(25). Further, LPS priming of monocytes and macrophages allows for activation of the inflammasome and IL-1β and IL-18 production following LL-37 stimulation(31, 32). In vivo, endogenous mCRAMP does not protect from LPS systemic effects, as both wild-type and mCRAMP−/− mice have similar rates of death in response to LPS-induced shock(33). Thus the ability of LL-37 to have a suppressive effect on LPS effects depends on the timing and context within which cells are exposed.

Other TLR receptor effects are also modulated by LL-37 exposure. LL-37 stabilizes TLR3 ligands and is able to enhance viral responses transmitted via this receptor in TLR3 transfected bronchial epithelial cells(34). In contrast, there is modulation of TLR3 responses in keratinocytes leading to repression of poly-IC mediated upregulation of CXCL10 and CCL5 but enhancement of poly-IC induced CXCL8(22). Flagellin activation of TLR5 is enhanced via LL-37 activation of src-family kinases(35). These observations again support the concept that LL-37 can enhance or abrogate inflammatory signals depending on cell-type and the microenvironment.

LL-37 modulates type I IFN responses

Type I IFNs are an important part of the innate immune response to microbes. They promote myeloid dendritic cell maturation and activation of lymphocytes and natural killer cells (36). Type I IFNs are also elevated in many autoimmune diseases such as lupus, dermatomyositis and psoriasis and likely contribute to disease pathogenesis(37). Synthesis of type I IFNs by plasmacytoid dendritic cells (pDCs) occurs via endosomal recognition of pathogen-derived nucleic acids by TLR7 and TLR9. Cytosolic DNA receptor activation by nucleic acids also results in type I IFN synthesis in other cell types(38). Activation of these pathways by self-DNA is prevented by degradation and inhibition of uptake.

The effects of LL-37 on type I IFN synthesis pathways are secondary to its positive charge and structure. Because of its high affinity for nucleic acids, LL-37 is able to bind DNA and act as a shuttle across membranes for nucleic acid delivery(39). In pDCs, DNA coupled with LL-37 (10µM) promotes access to the endosomal compartment, pDC maturation and TLR9 activation, thereby increasing type I IFN production. Further, LL-37 enhances double stranded DNA uptake by monocytes resulting in TLR-independent cytoplasmic DNA sensing via STING and TBK1 kinase mediated pathways leading to type I IFN production(40). Myeloid dendritic cells also are able to take-up extracellular DNA in the presence of LL-37, although less efficiently than pDCs or monocytes(40). Thus, the interactions of LL-37 with DNA may promote loss of tolerance to DNA and type I IFN synthesis, which may lead to aberrant immune responses following DNA exposure. Similar mechanisms of type I IFN induction have been demonstrated for LL-37 complexed with self-RNA released from dying cells which stimulates TLR7-mediated IFN-α production in pDCs(41).

LL-37 regulates other inflammatory signaling pathways

Activation of the P2X7R, a robust inducer of inflammasome activation in macrophages and monocytes, is considered a unique function of LL-37. This stimulation results in activation of both IL-1β and IL-18 (31, 32). Further, stimulation of this receptor by LL-37 enhances COX2 expression and prostaglandin E2 production via extracellular signal-regulated kinase (ERK) and c-Jun-N-terminal kinase in human gingival fibroblasts(42). Stimulation of IL-8 and CXCL3 release via activation of Src family kinase pathways downstream of P2X7R activation has been described in keratinocytes(35). Activation of the insulin-like growth factor 1 receptor, resulting in activation of the mitogen-activated protein kinase/ERK pathway by LL-37 has also been reported(43).

LL-37 regulates cell death

The effects of LL-37 on cell death regulation may be dependent on the cell type involved and the context in which the stimulation occurs. Activation of caspases 3 and 8 and induction of apoptosis in neutrophils is inhibited by LL-37(21). Higher doses of this peptide induce necrotic cell death in neutrophils, possibly secondary to overcoming inhibitory effects of membrane cholesterol on LL-37 pore forming abilities. Epithelial cells such as keratinocytes are also protected from camptothecin-induced apoptosis by LL-37 upregulation of COX-2(44). Additionally, intestinal epithelial cell cultures are protected from TRAIL-mediated apoptosis when pre-incubated with LL-37(26). Other cell types are more susceptible to pro-apoptotic effects of moderate doses of LL-37, inducing primary airway epithelial cells and osteoblasts(45).

Role of LL-37 in autoimmunity

Psoriasis

LL-37 levels are elevated in psoriatic skin (46) and significant interest regarding the role of this peptide in the pathogenesis of this disease has been evident. For a comprehensive review of the role of LL-37 in psoriasis pathogenesis, please see (47). Psoriasis is characterized by skin inflammation, keratinocyte proliferation, enhanced type I IFN signatures and overexpression of LL-37. Importantly, the presence of LL-37 in this disorder may contribute to disease pathogenesis. LL-37/DNA complexes generate stable ligands that may promote loss of tolerance and TLR-9 stimulation in psoriatic dermal pDCs. This results in type I IFN upregulation and further inflammatory pathway activation(48). Further, LL-37 has anti-apoptotic effects on keratinocytes, possibly contributing to the increased cellular proliferation present in this disorder(44). Cytosolic dsDNA can also stimulate activation and release of IL-1β in psoriasis, via activation of the AIM2 inflammasome(49). However, when delivered to the cytoplasm following complexing with LL-37, cytosolic DNA does not enhance IL-1β production or inflammasome activation, suggesting that LL-37 protects keratinocytes from dsDNA-mediated AIM2 inflammasome activation(49). Thus, the presence of elevated levels of LL-37 in psoriatic skin may shift the balance away from the “classical” inflammatory mediators (such as IL-1β) and instead drive a pathology driven by type I IFN responses. Research into the role of LL-37 in psoriasis pathogenesis is ongoing.

SLE

SLE is a heterogeneous systemic syndrome that can lead to severe organ manifestations driven by immune complex deposition and inflammation. The etiology of SLE remains elusive, but type I IFN pathways appear to be important contributors to disease development and severity(50). Recent evidence indicates that SLE neutrophils are primed to externalize DNA and other immunostimulatory molecules by enhanced synthesis and impaired degradation of neutrophil extracellular traps (NETs)(5153). In this regard, an important role for LL-37 in stabilizing immune complexes generated through NETs has been described in SLE patients(54). SLE-derived NETs from both normal density and low-density granulocytes externalize significant amounts of LL-37 (52, 55). This peptide protects NET-derived DNA from degradation(54). Coupled with anti-dsDNA antibodies, a hallmark of SLE, these circulating immune complexes of antibody, DNA and LL-37 are able to stimulate TLR9 in pDCs resulting in type I IFN production. Further, SLE patients demonstrate autoantibodies to LL-37 contributing to immune complex formation(54). These autoantibodies are able to induce NETs, thus perpetuating an inflammatory cycle and providing more NET material to stimulate type I IFN production(54).

Also potentially contributing to SLE pathogenesis is the pro-inflammatory effects of LL-37 on macrophages. Recombinant or NET-derived LL-37 stimulates inflammasome activation resulting in IL-1β and IL-18 production(31). IL-18 is elevated in SLE patients and correlates with disease activity and markers of cardiovascular disease(56, 57). Inflammasome activation in response to LL-37 is enhanced in M1 macrophages derived from SLE patients, resulting in elevated production of IL-18, which can induce further induce NETosis and thus promote a vicious inflammatory cycle resulting in disease development or flare (31).

In cutaneous lupus lesions, the upregulation of several antimicrobial peptides (AMPs), including LL-37 has been described(58). However, the effects of LL-37 upregulation in these lesions remain unknown. Some have speculated that these AMPs may provide a protective effect from cutaneous infection in cutaneous lupus erythematosus patients, but given the pro-inflammatory phenotype of LL-37 on macrophages(19), especially in SLE(31), further investigation into the role of LL-37 in lupus skin manifestations is warranted.

Arthritis and bone metabolism

Elevated expression of LL-37 and its activating protease have been described in RA patients(59, 60), and mechanistic studies are beginning to unravel the role of LL-37 in this disease. Periarticular osteopenia is a common finding among patients with RA(61), and LL-37 induces apoptosis of osteoblasts, which could contribute to reduced bone formation in arthritic joints(45). Further, a recent report characterized elevated expression of LL-37 primarily in the osteoclasts and granulocytes within the human RA synovium(62). Using a pristane-induced arthritis model in rats, upregulation of rCRAMP, the rat orthologue of LL-37, was demonstrated in granulocytes, macrophages and γδ T cells of synovial fluid. Importantly, transfer of pristane-exposed neutrophils induced arthritis, while type I IFN or autoantibody responses in control rats did not(62). This suggests that LL-37 may contribute to arthritis development, but further studies are needed to clarify its role.

An association between periodontal disease and the development of RA has been suggested, and treatment of periodontal disease can lead to improvement in markers of RA disease activity(63). LL-37 levels are increased in gingival crevicular fluid of chronic periodontal disease patients(64) and may play a role in promotion of gingival inflammation by increasing prostaglandin E2 production(42). Given the numerous pathways through which LL-37 can affect inflammatory cell types, further investigation into the role of gingival LL-37 and RA manifestations should be examined.

The risk of rheumatoid arthritis development is positively influenced by cigarette smoking, which is associated with development of anti-citrullinated protein antibodies and correlates with disease activity(65). Cigarette smoke is able to induce upregulation of mCRAMP via NF-κB pathways, and recruitment of macrophages and neutrophils into the lung following smoke exposure was highly dependent on the presence of mCRAMP(66). Further, cigarette smoke exposure enhances the enzymatic activity of peptidylarginine deiminase 2 resulting in enhanced citrullination of proteins(67), including LL-37 itself, which increases its chemotactic properties(68). Because neutrophils are prone to NETosis in RA patients and NETs are a source of citrullinated antigens in RA(69, 70), the role of LL-37, and its citrullinated form, in enhancing cigarette smoke-related RA risk factors should be explored.

Other autoimmune diseases

In addition to the diseases mentioned above, reports exist of potential roles for LL-37 in other autoimmune disorders. LL-37 may have a potentially protective role in the development of sarcoidosis, as transcript levels are repressed in more severe disease. This is ascribed to TNFα effects, which negatively affect LL-37 expression in alveolar macrophages(71). Additionally, nasal secretions from patients with granulomatosis with polyangiitis (formerly known as Wegener’s) colonized with Staph aureus, a potentially pathogenic bacteria in this disease, show significantly elevated levels of LL-37(72). However, whether the elevated levels of this peptide are pro-inflammatory or protective in this disease remain to be determined.

The role of LL-37 in atherosclerosis

Atherosclerosis is considered an inflammatory disease (73) in which innate immune pathways, including upregulation of type I interferons (IFN), are activated in atherosclerotic plaques and contribute to disease development(7477). A participation of LL-37 bound to immune complexes that promote type I IFN production and stimulate atherosclerosis development has been proposed(78). Transcription of LL-37 is elevated in human atherosclerotic aortas(79) and its association with neo-intima associated macrophages has been demonstrated(80). Further, pro-atherosclerotic Apoe −/− mice demonstrate elevated neutrophil-associated mCRAMP in the carotid arteries of mice fed high fat chow. These mice lose mCRAMP staining and have substantial protection in plaque size and macrophage recruitment when crossed to mCRAMP −/− mice(81). This suggests that LL-37 plays an important role in recruitment of inflammatory cells to plaques as well as modulation of the plaque cytokine environment to promote atherosclerotic lesion development.

In addition to plaque promotion, LL-37 also has effects on endothelial cells. LL-37 induces endothelial cell activation and upregulation of intracellular adhesion molecule-1, which participates in inflammatory cell recruitment to plaque(82). Further, while this response may be important for vasculogenesis and wound vascularization, it may be pro-thrombotic in the context of atherosclerotic lesions. Interestingly, when used to coat coronary stents, LL-37 prevented in-stent rethrombosis by promotion of the re-epithelialization of the stent which limited neo-intimal hyperplasia(83). Thus, the effects of LL-37 on atherosclerosis are also likely dual in that it promotes atherosclerotic inflammation but may facilitate vascular healing.

Therapeutic uses of LL-37?

Because of their antimicrobial properties, AMPs have been a promising target for drug development as alternatives to systemic antibiotics(reviewed in (84). However, others have cautioned that exposure to manufactured peptides may induce microbial resistance to innate human defenses against microbial invasion(85). Indeed, various antibiotics with cathelicidin-like properties can promote microbial resistance to LL-37(86). Given the rapidly evolving role of LL-37 in autoimmune diseases, this molecule could potentially serve as a target for immune modulation as well. Neutralization of TLR4 signaling has shown promise in diseases such as colitis, chronic pain, and sepsis (reviewed in (87). Given the effects of LL-37 on this receptor, it may have potential as a therapy in diseases impacted by TLR4 signaling. For diseases where LL-37 may promote TLR7 and 9 signaling, such as psoriasis and SLE, antagonism of this peptide may provide a therapeutic target. Because LL-37 is able to participate in immune complex formation(54), caution should be exercised if attempts to neutralize this peptide using antibodies are considered. Further, the consequences of blockade of this peptide on antimicrobial defenses will need to be carefully studied.

Conclusions

The innate immune system is gaining attention for its contributions to autoimmune disease development. For LL-37, this peptide is produced in environments where it is prone to interact with microbes. Some of the functions of LL-37 are anti-inflammatory, particularly those involved in blocking gram negative signaling pathways through TLR4. However, in the context of the inflammatory response, this peptide may also provide pro-inflammatory signals which can propagate inflammation, stimulate type I IFN production and result in induction of autoimmune diseases. Further research is needed to fully understand the big effects of this little peptide on immune system function so that potential therapeutic uses can be explored.

Acknowledgments

This work was supported by the National Institutes of Health (NIH) through Project Grants F032521 (to JMK) and F033615 (to MJK).

References Cited

  • 1.Wang Z, Wang G. APD: the Antimicrobial Peptide Database. Nucleic Acids Research. 2004;32:D590–D592. doi: 10.1093/nar/gkh025. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Larrick JW, Hirata M, Balint RF, Lee J, Zhong J, Wright SC. Human CAP18: a novel antimicrobial lipopolysaccharide-binding protein. Infect Immun. 1995;63:1291–1297. doi: 10.1128/iai.63.4.1291-1297.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Yamasaki K, Schauber J, Coda A, Lin H, Dorschner RA, Schechter NM, Bonnart C, Descargues P, Hovnanian A, Gallo RL. Kallikrein-mediated proteolysis regulates the antimicrobial effects of cathelicidins in skin. Faseb J. 2006;20:2068–2080. doi: 10.1096/fj.06-6075com. [DOI] [PubMed] [Google Scholar]
  • 4.Sørensen OE, Follin P, Johnsen AH, Calafat J, Tjabringa GS, Hiemstra PS, Borregaard N. Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. Blood. 2001;97:3951–3959. doi: 10.1182/blood.v97.12.3951. [DOI] [PubMed] [Google Scholar]
  • 5.Oren Z, Lerman JC, Gudmundsson GH, Agerberth B, Shai Y. Structure and organization of the human antimicrobial peptide LL-37 in phospholipid membranes: relevance to the molecular basis for its non-cell-selective activity. Biochem. J. 1999;341:501–513. [PMC free article] [PubMed] [Google Scholar]
  • 6.Bucki R, Janmey PA. Interaction of the Gelsolin-Derived Antibacterial PBP 10 Peptide with Lipid Bilayers and Cell Membranes. Antimicrob. Agents Chemother. 2006;50:2932–2940. doi: 10.1128/AAC.00134-06. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Turner J, Cho Y, Dinh NN, Waring AJ, Lehrer RI. Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils. Antimicrob Agents Chemother. 1998;42:2206–2214. doi: 10.1128/aac.42.9.2206. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Lee C-C, Sun Y, Qian S, Huang Huey W. Transmembrane Pores Formed by Human Antimicrobial Peptide LL-37. Biophysical Journal. 2011;100:1688–1696. doi: 10.1016/j.bpj.2011.02.018. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Ding B, Soblosky L, Nguyen K, Geng J, Yu X, Ramamoorthy A, Chen Z. Physiologically-Relevant Modes of Membrane Interactions by the Human Antimicrobial Peptide, LL-37, Revealed by SFG Experiments. Sci. Rep. 2013;3 doi: 10.1038/srep01854. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Vandamme D, Landuyt B, Luyten W, Schoofs L. A comprehensive summary of LL-37, the factotum human cathelicidin peptide. Cellular Immunology. 2012;280:22–35. doi: 10.1016/j.cellimm.2012.11.009. [DOI] [PubMed] [Google Scholar]
  • 11.Schauber J, Gallo RL. The vitamin D pathway: a new target for control of the skin's immune response? Exp Dermatol. 2008;17:633–639. doi: 10.1111/j.1600-0625.2008.00768.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Park K, Elias PM, Oda Y, Mackenzie D, Mauro T, Holleran WM, Uchida Y. Regulation of cathelicidin antimicrobial peptide expression by an endoplasmic reticulum (ER) stress signaling, vitamin D receptor-independent pathway. J Biol Chem. 2011;286:34121–34130. doi: 10.1074/jbc.M111.250431. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Liu PT, Stenger S, Tang DH, Modlin RL. Cutting Edge: Vitamin D-Mediated Human Antimicrobial Activity against Mycobacterium tuberculosis Is Dependent on the Induction of Cathelicidin. The journal of immunology. 2007;179:2060–2063. doi: 10.4049/jimmunol.179.4.2060. [DOI] [PubMed] [Google Scholar]
  • 14.Nizet V, Ohtake T, Lauth X, Trowbridge J, Rudisill J, Dorschner RA, Pestonjamasp V, Piraino J, Huttner K, Gallo RL. Innate antimicrobial peptide protects the skin from invasive bacterial infection. Nature. 2001;414:454–457. doi: 10.1038/35106587. [DOI] [PubMed] [Google Scholar]
  • 15.Iimura M, Gallo RL, Hase K, Miyamoto Y, Eckmann L, Kagnoff MF. Cathelicidin Mediates Innate Intestinal Defense against Colonization with Epithelial Adherent Bacterial Pathogens. The journal of immunology. 2005;174:4901–4907. doi: 10.4049/jimmunol.174.8.4901. [DOI] [PubMed] [Google Scholar]
  • 16.Chromek M, Slamova Z, Bergman P, Kovacs L, Podracka L, Ehren I, Hokfelt T, Gudmundsson GH, Gallo RL, Agerberth B, Brauner A. The antimicrobial peptide cathelicidin protects the urinary tract against invasive bacterial infection. Nat Med. 2006;12:636–641. doi: 10.1038/nm1407. [DOI] [PubMed] [Google Scholar]
  • 17.Hing TC, Ho S, Shih DQ, Ichikawa R, Cheng M, Chen J, Chen X, Law I, Najarian R, Kelly CP, Gallo RL, Targan SR, Pothoulakis C, Koon HW. The antimicrobial peptide cathelicidin modulates Clostridium difficile-associated colitis and toxin A-mediated enteritis in mice. Gut. 2012 doi: 10.1136/gutjnl-2012-302180. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Barlow PG, Svoboda P, Mackellar A, Nash AA, York IA, Pohl J, Davidson DJ, Donis RO. Antiviral Activity and Increased Host Defense against Influenza Infection Elicited by the Human Cathelicidin LL-37. PLoS One. 2011;6:e25333. doi: 10.1371/journal.pone.0025333. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.van der Does AM, Beekhuizen H, Ravensbergen B, Vos T, Ottenhoff THM, van Dissel JT, Drijfhout JW, Hiemstra PS, Nibbering PH. LL-37 Directs Macrophage Differentiation toward Macrophages with a Proinflammatory Signature. The journal of immunology. 2010;185:1442–1449. doi: 10.4049/jimmunol.1000376. [DOI] [PubMed] [Google Scholar]
  • 20.Yu J, Mookherjee N, Wee K, Bowdish DME, Pistolic J, Li Y, Rehaume L, Hancock REW. Host Defense Peptide LL-37, in Synergy with Inflammatory Mediator IL-1β, Augments Immune Responses by Multiple Pathways. The journal of immunology. 2007;179:7684–7691. doi: 10.4049/jimmunol.179.11.7684. [DOI] [PubMed] [Google Scholar]
  • 21.Barlow PG, Li Y, Wilkinson TS, Bowdish DME, Lau YE, Cosseau C, Haslett C, Simpson AJ, Hancock REW, Davidson DJ. The human cationic host defense peptide LL-37 mediates contrasting effects on apoptotic pathways in different primary cells of the innate immune system. Journal of leukocyte biology. 2006;80:509–520. doi: 10.1189/jlb.1005560. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Chen X, Takai T, Xie Y, Niyonsaba F, Okumura K, Ogawa H. Human antimicrobial peptide LL-37 modulates proinflammatory responses induced by cytokine milieus and double-stranded RNA in human keratinocytes. Biochemical and Biophysical Research Communications. 2013;433:532–537. doi: 10.1016/j.bbrc.2013.03.024. [DOI] [PubMed] [Google Scholar]
  • 23.Tjabringa GS, Ninaber DK, Drijfhout JW, Rabe KF, Hiemstra PS. Human Cathelicidin LL-37 Is a Chemoattractant for Eosinophils and Neutrophils That Acts via Formyl-Peptide Receptors. International Archives of Allergy and Immunology. 2006;140:103–112. doi: 10.1159/000092305. [DOI] [PubMed] [Google Scholar]
  • 24.Tokumaru S, Sayama K, Shirakata Y, Komatsuzawa H, Ouhara K, Hanakawa Y, Yahata Y, Dai X, Tohyama M, Nagai H, Yang L, Higashiyama S, Yoshimura A, Sugai M, Hashimoto K. Induction of Keratinocyte Migration via Transactivation of the Epidermal Growth Factor Receptor by the Antimicrobial Peptide LL-37. The journal of immunology. 2005;175:4662–4668. doi: 10.4049/jimmunol.175.7.4662. [DOI] [PubMed] [Google Scholar]
  • 25.Scott MG, Davidson DJ, Gold MR, Bowdish D, Hancock REW. The Human Antimicrobial Peptide LL-37 Is a Multifunctional Modulator of Innate Immune Responses. The journal of immunology. 2002;169:3883–3891. doi: 10.4049/jimmunol.169.7.3883. [DOI] [PubMed] [Google Scholar]
  • 26.Otte J-M, Zdebik A-E, Brand S, Chromik AM, Strauss S, Schmitz F, Steinstraesser L, Schmidt WE. Effects of the cathelicidin LL-37 on intestinal epithelial barrier integrity. Regulatory Peptides. 2009;156:104–117. doi: 10.1016/j.regpep.2009.03.009. [DOI] [PubMed] [Google Scholar]
  • 27.Lee YH, Lee HS, Choi SJ, Ji JD, Song GG. Associations between TLR polymorphisms and systemic lupus erythematosus: a systematic review and meta-analysis. Clinical and experimental rheumatology. 2012;30:262–265. [PubMed] [Google Scholar]
  • 28.Rosenfeld Y, Papo N, Shai Y. Endotoxin (Lipopolysaccharide) Neutralization by Innate Immunity Host-Defense Peptides: PEPTIDE PROPERTIES AND PLAUSIBLE MODES OF ACTION. Journal of Biological Chemistry. 2006;281:1636–1643. doi: 10.1074/jbc.M504327200. [DOI] [PubMed] [Google Scholar]
  • 29.Di Nardo A, Braff MH, Taylor KR, Na C, Granstein RD, McInturff JE, Krutzik S, Modlin RL, Gallo RL. Cathelicidin antimicrobial peptides block dendritic cell TLR4 activation and allergic contact sensitization. J Immunol. 2007;178:1829–1834. doi: 10.4049/jimmunol.178.3.1829. [DOI] [PubMed] [Google Scholar]
  • 30.Brown KL, Poon GF, Birkenhead D, Pena OM, Falsafi R, Dahlgren C, Karlsson A, Bylund J, Hancock RE, Johnson P. Host defense peptide LL-37 selectively reduces proinflammatory macrophage responses. J Immunol. 2011;186:5497–5505. doi: 10.4049/jimmunol.1002508. [DOI] [PubMed] [Google Scholar]
  • 31.Kahlenberg JM, Carmona-Rivera C, Smith CK, Kaplan MJ. Neutrophil Extracellular Trap-Associated Protein Activation of the NLRP3 Inflammasome Is Enhanced in Lupus Macrophages. The journal of immunology. 2013;190:1217–1226. doi: 10.4049/jimmunol.1202388. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Elssner A, Duncan M, Gavrilin M, Wewers MD. A novel P2X7 receptor activator, the human cathelicidin-derived peptide LL37, induces IL-1 beta processing and release. J Immunol. 2004;172:4987–4994. doi: 10.4049/jimmunol.172.8.4987. [DOI] [PubMed] [Google Scholar]
  • 33.Pinheiro da, Silva F, Gallo RL, Nizet V. Differing effects of exogenous or endogenous cathelicidin on macrophage toll-like receptor signaling. Immunol Cell Biol. 2009;87:496–500. doi: 10.1038/icb.2009.19. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Lai Y, Adhikarakunnathu S, Bhardwaj K, Ranjith-Kumar CT, Wen Y, Jordan JL, Wu LH, Dragnea B, Mateo LS, Kao CC. LL37 and Cationic Peptides Enhance TLR3 Signaling by Viral Double-stranded RNAs. PLoS One. 2011;6:e26632. doi: 10.1371/journal.pone.0026632. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Nijnik A, Pistolic J, Filewod NC, Hancock RE. Signaling pathways mediating chemokine induction in keratinocytes by cathelicidin LL-37 and flagellin. J Innate Immun. 2012;4:377–386. doi: 10.1159/000335901. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Stetson DB, Medzhitov R. Type I Interferons in Host Defense. Immunity. 2006;25:373–381. doi: 10.1016/j.immuni.2006.08.007. [DOI] [PubMed] [Google Scholar]
  • 37.Rönnblom L, Eloranta M-L. The interferon signature in autoimmune diseases. Current opinion in rheumatology. 2013;25:248–253. doi: 10.1097/BOR.0b013e32835c7e32. 210.1097/BOR.1090b1013e32835c32837e32832. [DOI] [PubMed] [Google Scholar]
  • 38.Atianand MK, Fitzgerald KA. Molecular Basis of DNA Recognition in the Immune System. The journal of immunology. 2013;190:1911–1918. doi: 10.4049/jimmunol.1203162. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Zhang X, Oglęcka K, Sandgren S, Belting M, Esbjörner EK, Nordén B, Gräslund A. Dual functions of the human antimicrobial peptide LL-37—Target membrane perturbation and host cell cargo delivery. Biochimica et Biophysica Acta (BBA) - Biomembranes. 2010;1798:2201–2208. doi: 10.1016/j.bbamem.2009.12.011. [DOI] [PubMed] [Google Scholar]
  • 40.Chamilos G, Gregorio J, Meller S, Lande R, Kontoyiannis DP, Modlin RL, Gilliet M. Cytosolic sensing of extracellular self-DNA transported into monocytes by the antimicrobial peptide LL37. Blood. 2012;120:3699–3707. doi: 10.1182/blood-2012-01-401364. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Ganguly D, Chamilos G, Lande R, Gregorio J, Meller S, Facchinetti V, Homey B, Barrat FJ, Zal T, Gilliet M. Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8. J Exp Med. 2009;206:1983–1994. doi: 10.1084/jem.20090480. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Chotjumlong P, Bolscher JG, Nazmi K, Reutrakul V, Supanchart C, Buranaphatthana W, Krisanaprakornkit S. Involvement of the P2X7 purinergic receptor and c-Jun N-terminal and extracellular signal-regulated kinases in cyclooxygenase-2 and prostaglandin E2 induction by LL-37. J Innate Immun. 2013;5:72–83. doi: 10.1159/000342928. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Girnita A, Zheng H, Gronberg A, Girnita L, Stahle M. Identification of the cathelicidin peptide LL-37 as agonist for the type I insulin-like growth factor receptor. Oncogene. 2011 doi: 10.1038/onc.2011.239. [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
  • 44.Chamorro CI, Weber G, Gronberg A, Pivarcsi A, Stahle M. The Human Antimicrobial Peptide LL-37 Suppresses Apoptosis in Keratinocytes. The Journal of investigative dermatology. 2008;129:937–944. doi: 10.1038/jid.2008.321. [DOI] [PubMed] [Google Scholar]
  • 45.Säll J, Carlsson M, Gidlöf O, Holm A, Humlén J, Öhman J, Svensson D, Nilsson BO, Jönsson D. The Antimicrobial Peptide LL-37 Alters Human Osteoblast Ca<sup>2+</sup> Handling and Induces Ca<sup>2+</sup>-Independent Apoptosis. Journal of innate immunity. 2013;5:290–300. doi: 10.1159/000346587. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Ong PY, Ohtake T, Brandt C, Strickland I, Boguniewicz M, Ganz T, Gallo RL, Leung DYM. Endogenous Antimicrobial Peptides and Skin Infections in Atopic Dermatitis. New England Journal of Medicine. 2002;347:1151–1160. doi: 10.1056/NEJMoa021481. [DOI] [PubMed] [Google Scholar]
  • 47.Reinholz M, Ruzicka T, Schauber J. Cathelicidin LL-37: An Antimicrobial Peptide with a Role in Inflammatory Skin Disease. Ann Dermatol. 2012;24:126–135. doi: 10.5021/ad.2012.24.2.126. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Lande R, Gregorio J, Facchinetti V, Chatterjee B, Wang YH, Homey B, Cao W, Su B, Nestle FO, Zal T, Mellman I, Schroder JM, Liu YJ, Gilliet M. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature. 2007;449:564–569. doi: 10.1038/nature06116. [DOI] [PubMed] [Google Scholar]
  • 49.Dombrowski Y, Peric M, Koglin S, Kammerbauer C, Göβ C, Anz D, Simanski M, Gläser R, Harder J, Hornung V, Gallo RL, Ruzicka T, Besch R, Schauber J. Cytosolic DNA Triggers Inflammasome Activation in Keratinocytes in Psoriatic Lesions. Science translational medicine. 2011;3:82ra38. doi: 10.1126/scitranslmed.3002001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Elkon KB, Santer DM. Complement, interferon and lupus. Curr Opin Immunol. 2012;24:665–670. doi: 10.1016/j.coi.2012.08.004. [DOI] [PubMed] [Google Scholar]
  • 51.Hakkim A, Furnrohr BG, Amann K, Laube B, Abed UA, Brinkmann V, Herrmann M, Voll RE, Zychlinsky A. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc Natl Acad Sci U S A. 2010;107:9813–9818. doi: 10.1073/pnas.0909927107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Garcia-Romo GS, Caielli S, Vega B, Connolly J, Allantaz F, Xu Z, Punaro M, Baisch J, Guiducci C, Coffman RL, Barrat FJ, Banchereau J, Pascual V. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med. 2011;3:73ra20. doi: 10.1126/scitranslmed.3001201. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Villanueva E, Yalavarthi S, Berthier CC, Hodgin JB, Khandpur R, Lin AM, Rubin CJ, Zhao W, Olsen SH, Klinker M, Shealy D, Denny MF, Plumas J, Chaperot L, Kretzler M, Bruce AT, Kaplan MJ. Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J Immunol. 2011;187:538–552. doi: 10.4049/jimmunol.1100450. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Lande R, Ganguly D, Facchinetti V, Frasca L, Conrad C, Gregorio J, Meller S, Chamilos G, Sebasigari R, Riccieri V, Bassett R, Amuro H, Fukuhara S, Ito T, Liu YJ, Gilliet M. Neutrophils Activate Plasmacytoid Dendritic Cells by Releasing Self-DNA-Peptide Complexes in Systemic Lupus Erythematosus. Sci Transl Med. 2011;3:73ra19. doi: 10.1126/scitranslmed.3001180. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Denny M, Yalavarthi S, Zhao W, Thacker S, Anderson M, Sandy A, McCune WJ, Kaplan M. A distinct subset of proinflammatory neutrophils isolated from patients with systemic lupus erythematosus induces vascular damage and synthesizes type I IFNs. The journal of immunology. 2010;184:3284–3297. doi: 10.4049/jimmunol.0902199. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Kahlenberg JM, Thacker SG, Berthier CC, Cohen CD, Kretzler M, Kaplan MJ. Inflammasome activation of IL-18 results in endothelial progenitor cell dysfunction in systemic lupus erythematosus. J Immunol. 2011;187:6143–6156. doi: 10.4049/jimmunol.1101284. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Favilli F, Anzilotti C, Martinelli L, Quattroni P, Martino SD, Pratesi F, Neumann D, Beermann S, Novick D, Dinarello CA, Boraschi D, Migliorini P. IL-18 Activity in Systemic Lupus Erythematosus. Annals of the New York Academy of Sciences. 2009;1173:301–309. doi: 10.1111/j.1749-6632.2009.04742.x. [DOI] [PubMed] [Google Scholar]
  • 58.Kreuter A, Jaouhar M, Skrygan M, Tigges C, Stücker M, Altmeyer P, Gläser R, Gambichler T. Expression of antimicrobial peptides in different subtypes of cutaneous lupus erythematosus. Journal of the American Academy of Dermatology. 2011;65:125–133. doi: 10.1016/j.jaad.2010.12.012. [DOI] [PubMed] [Google Scholar]
  • 59.Matsumoto T, Kaneko T, Seto M, Wada H, Kobayashi T, Nakatani K, Tonomura H, Tono Y, Ohyabu M, Nobori T, Shiku H, Sudo A, Uchida A, Kurosawa DJ, Kurosawa S. The membrane proteinase 3 expression on neutrophils was downregulated after treatment with infliximab in patients with rheumatoid arthritis. Clin Appl Thromb Hemost. 2008;14:186–192. doi: 10.1177/1076029607303961. [DOI] [PubMed] [Google Scholar]
  • 60.Paulsen F, Pufe T, Conradi L, Varoga D, Tsokos M, Papendieck J, Petersen W. Antimicrobial peptides are expressed and produced in healthy and inflamed human synovial membranes. The Journal of pathology. 2002;198:369–377. doi: 10.1002/path.1224. [DOI] [PubMed] [Google Scholar]
  • 61.Deal C. Bone Loss in Rheumatoid Arthritis: Systemic, Periarticular, and Focal. Current Rheumatology Reports. 2012;14:231–237. doi: 10.1007/s11926-012-0253-7. [DOI] [PubMed] [Google Scholar]
  • 62.Hoffmann MH, Bruns H, Backdahl L, Neregard P, Niederreiter B, Herrmann M, Catrina AI, Agerberth B, Holmdahl R. The cathelicidins LL-37 and rCRAMP are associated with pathogenic events of arthritis in humans and rats. Ann Rheum Dis. 2012 doi: 10.1136/annrheumdis-2012-202218. [DOI] [PubMed] [Google Scholar]
  • 63.Kaur S, White S, Bartold PM. Periodontal Disease and Rheumatoid Arthritis: A Systematic Review. Journal of Dental Research. 2013;92:399–408. doi: 10.1177/0022034513483142. [DOI] [PubMed] [Google Scholar]
  • 64.Türkoğlu O, Emingil G, Kütükçüler N, Atilla G. Gingival Crevicular Fluid Levels of Cathelicidin LL-37 and Interleukin-18 in Patients With Chronic Periodontitis. Journal of Periodontology. 2009;80:969–976. doi: 10.1902/jop.2009.080532. [DOI] [PubMed] [Google Scholar]
  • 65.Wolfe F. The effect of smoking on clinical, laboratory, and radiographic status in rheumatoid arthritis. J Rheumatol. 2000;27:630–637. [PubMed] [Google Scholar]
  • 66.Li D, Beisswenger C, Herr C, Schmid RM, Gallo RL, Han G, Zakharkina T, Bals R. Expression of the antimicrobial peptide cathelicidin in myeloid cells is required for lung tumor growth. Oncogene. 2013 doi: 10.1038/onc.2013.248. [DOI] [PubMed] [Google Scholar]
  • 67.Makrygiannakis D, Hermansson M, Ulfgren A-K, Nicholas AP, Zendman AJW, Eklund A, Grunewald J, Skold CM, Klareskog L, Catrina AI. Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells. Annals of the Rheumatic Diseases. 2008;67:1488–1492. doi: 10.1136/ard.2007.075192. [DOI] [PubMed] [Google Scholar]
  • 68.Kilsgård O, Andersson P, Malmsten M, Nordin SL, Linge HM, Eliasson M, Sörenson E, Erjefält JS, Bylund J, Olin AI, Sørensen OE, Egesten A. Peptidylarginine Deiminases Present in the Airways during Tobacco Smoking and Inflammation Can Citrullinate the Host Defense Peptide LL-37, Resulting in Altered Activities. American Journal of Respiratory Cell and Molecular Biology. 2012;46:240–248. doi: 10.1165/rcmb.2010-0500OC. [DOI] [PubMed] [Google Scholar]
  • 69.Pratesi F, Dioni I, Tommasi C, Alcaro MC, Paolini I, Barbetti F, Boscaro F, Panza F, Puxeddu I, Rovero P, Migliorini P. Antibodies from patients with rheumatoid arthritis target citrullinated histone 4 contained in neutrophils extracellular traps. Annals of the Rheumatic Diseases. 2013 doi: 10.1136/annrheumdis-2012-202765. [DOI] [PubMed] [Google Scholar]
  • 70.Khandpur R, Carmona-Rivera C, Vivekanandan-Giri A, Gizinski A, Yalavarthi S, Knight JS, Friday S, Li S, Patel RM, Subramanian V, Thompson P, Chen P, Fox DA, Pennathur S, Kaplan MJ. NETs Are a Source of Citrullinated Autoantigens and Stimulate Inflammatory Responses in Rheumatoid Arthritis. Science translational medicine. 2013;5:178ra140. doi: 10.1126/scitranslmed.3005580. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.Barna BP, Culver DA, Kanchwala A, Singh RJ, Huizar I, Abraham S, Malur A, Marshall I, Kavuru MS, Thomassen MJ. Alveolar macrophage cathelicidin deficiency in severe sarcoidosis. J Innate Immun. 2012;4:569–578. doi: 10.1159/000339149. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.Hui Y. Antimicrobial peptides in nasal secretion and mucosa with respect to S. aureus colonisation in Wegener´s granulomatosis. Clinical and experimental rheumatology. 2011;29:S49–S56. [PubMed] [Google Scholar]
  • 73.Hansson GK. Inflammation, Atherosclerosis, and Coronary Artery Disease. New England Journal of Medicine. 2005;352:1685–1695. doi: 10.1056/NEJMra043430. [DOI] [PubMed] [Google Scholar]
  • 74.Zhao WSE, McCune WJ, Kaplan MJ. Type I Interferon signatures are associated with vascular risk and atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2009;59(suppl) [Google Scholar]
  • 75.Doring Y, Zernecke A. Plasmacytoid dendritic cells in atherosclerosis. Front Physiol. 2012;3:230. doi: 10.3389/fphys.2012.00230. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76.Niessner A, Sato K, Chaikof EL, Colmegna I, Goronzy JJ, Weyand CM. Pathogen-sensing plasmacytoid dendritic cells stimulate cytotoxic T-cell function in the atherosclerotic plaque through interferon-alpha. Circulation. 2006;114:2482–2489. doi: 10.1161/CIRCULATIONAHA.106.642801. [DOI] [PubMed] [Google Scholar]
  • 77.Gage J, Hasu M, Thabet M, Whitman SC. Caspase-1 Deficiency Decreases Atherosclerosis in Apolipoprotein E-Null Mice. Canadian Journal of Cardiology. 2012;28:222–229. doi: 10.1016/j.cjca.2011.10.013. [DOI] [PubMed] [Google Scholar]
  • 78.Doring Y, Manthey HD, Drechsler M, Lievens D, Megens RT, Soehnlein O, Busch M, Manca M, Koenen RR, Pelisek J, Daemen MJ, Lutgens E, Zenke M, Binder CJ, Weber C, Zernecke A. Auto-antigenic protein-DNA complexes stimulate plasmacytoid dendritic cells to promote atherosclerosis. Circulation. 2012;125:1673–1683. doi: 10.1161/CIRCULATIONAHA.111.046755. [DOI] [PubMed] [Google Scholar]
  • 79.Edfeldt K, Agerberth B, Rottenberg ME, Gudmundsson GH, Wang X-B, Mandal K, Xu Q, Yan Z-q. Involvement of the Antimicrobial Peptide LL-37 in Human Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology. 2006;26:1551–1557. doi: 10.1161/01.ATV.0000223901.08459.57. [DOI] [PubMed] [Google Scholar]
  • 80.Ciornei C, Tapper H, Bjartell A, Sternby N, Bodelsson M. Human antimicrobial peptide LL-37 is present in atherosclerotic plaques and induces death of vascular smooth muscle cells: a laboratory study. BMC Cardiovascular Disorders. 2006;6:49. doi: 10.1186/1471-2261-6-49. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 81.Doring Y, Drechsler M, Wantha S, Kemmerich K, Lievens D, Vijayan S, Gallo RL, Weber C, Soehnlein O. Lack of neutrophil-derived CRAMP reduces atherosclerosis in mice. Circ Res. 2012;110:1052–1056. doi: 10.1161/CIRCRESAHA.112.265868. [DOI] [PubMed] [Google Scholar]
  • 82.Koczulla R, von Degenfeld G, Kupatt C, Krotz F, Zahler S, Gloe T, Issbrucker K, Unterberger P, Zaiou M, Lebherz C, Karl A, Raake P, Pfosser A, Boekstegers P, Welsch U, Hiemstra PS, Vogelmeier C, Gallo RL, Clauss M, Bals R. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J Clin Invest. 2003;111:1665–1672. doi: 10.1172/JCI17545. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 83.Soehnlein O, Wantha S, Simsekyilmaz S, Döring Y, Megens RTA, Mause SF, Drechsler M, Smeets R, Weinandy S, Schreiber F, Gries T, Jockenhoevel S, Möller M, Vijayan S, van Zandvoort MAMJ, Agerberth B, Pham CT, Gallo RL, Hackeng TM, Liehn EA, Zernecke A, Klee D, Weber C. Neutrophil-Derived Cathelicidin Protects from Neointimal Hyperplasia. Science translational medicine. 2011;3:103ra198. doi: 10.1126/scitranslmed.3002531. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 84.Kruse T, Kristensen HH. Using antimicrobial host defense peptides as anti-infective and immunomodulatory agents. Expert Rev Anti Infect Ther. 2008;6:887–895. doi: 10.1586/14787210.6.6.887. [DOI] [PubMed] [Google Scholar]
  • 85.Habets MGJL, Brockhurst MA. Therapeutic antimicrobial peptides may compromise natural immunity. Biology Letters. 2012;8:416–418. doi: 10.1098/rsbl.2011.1203. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 86.Napier BA, Burd EM, Satola SW, Cagle SM, Ray SM, McGann P, Pohl J, Lesho EP, Weiss DS. Clinical Use of Colistin Induces Cross-Resistance to Host Antimicrobials in Acinetobacter baumannii. mBio. 2013;4 doi: 10.1128/mBio.00021-13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 87.Hennessy EJ, Parker AE, O'Neill LAJ. Targeting Toll-like receptors: emerging therapeutics? Nat Rev Drug Discov. 2010;9:293–307. doi: 10.1038/nrd3203. [DOI] [PubMed] [Google Scholar]

RESOURCES